undamentalytics Newsletter

Bienaime Jean Jacques: insider trades

Chief executive, Director at 6 companies we cover. 28 open-market purchases and 48 sales not made under a pre-set plan, reported from March 1, 2010 to August 19, 2026.

Would copying Bienaime Jean Jacques’s purchases have beaten the S&P 500?

Too few purchases to judge. Only 13 purchases have 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. Buying each purchase the day after it was reported, an equal amount each, and holding it 12 months or until they reported a sale would have turned $10,000 on March 2, 2010 into $3,622 by November 2, 2026, −5.9% a year. The copy held shares only 35% of the time, so the fair comparison is the S&P 500 on those same days with Treasury bills otherwise: $22,636, +5.0% a year (the S&P 500 held throughout made $90,567, +14.2% a year). Beta against the index was 0.45. Twelve months after each report, the average purchase was −5.6% against the S&P 500 (median −53.0%), and 31% beat it. Measured from the trade date, the insider’s own timing, the average was −5.8%. After their sales, the shares moved +11.5% against the index over 12 months on average (a negative figure means selling was the right call); 32% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

$0$50.0k$100k 201020122014201620182020202220242026 $90.6k$22.6k$3.6k
Copying Bienaime Jean JacquesS&P 500, same days investedS&P 500, held throughout $10,000 copying Bienaime Jean Jacques’s open-market purchases from March 2, 2010, before costs and taxes, marked weekly. Each purchase gets the same starting stake, bought at the close of the first trading day after the report and sold 12 months later or the day after a reported sale of that stock; uninvested money earns the Treasury bill rate. “Same days invested” holds the S&P 500 only on the days the copy held shares, Treasury bills otherwise.
Return a year, copying
−5.9%
S&P 500, same days invested
+5.0% (held throughout +14.2%)
Time in shares
35%
Sharpe ratio (S&P 500)
0.08 (0.77)
Biggest drop (S&P 500)
−96% (−34%)
Market sensitivity (beta)
0.45
Purchases copied
24

Trade by trade

Bienaime Jean Jacques: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 23 +3.2% −0.6% 48% 7 1.00 0.36 No reliable evidence
Purchases, 6 months after the report 16 +2.6% −14.2% 44% 7 0.71 0.51 No reliable evidence
Purchases, 12 months after the report 13 −5.6% −53.0% 31% 6 −0.19 0.86 No reliable evidence
Purchases, 12 months after the trade 13 −5.8% −48.2% 39% 6 −0.22 0.84 No reliable evidence
Sales, 3 months after the report 48 +2.4% +3.9% 44% 13 0.26 0.80 No reliable evidence
Sales, 12 months after the report 47 +11.5% +18.6% 32% 12 −0.19 0.85 No reliable evidence
Sales, 12 months after the trade 47 +10.9% +18.3% 34% 12 −0.22 0.83 No reliable evidence

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Biomarin Pharmaceutical Inc BMRN Chief Executive Officer145March 1, 2010March 7, 2024
Immunome Inc. IMNM —81May 22, 2024June 9, 2026
Incyte INCY —62April 11, 2017November 12, 2020
Keros Therapeutics, Inc. KROS —60March 11, 2026August 19, 2026
Immunic, Inc. IMUX —40October 9, 2014September 14, 2017
Ascendis Pharma A/s ASND —30May 27, 2026August 18, 2026

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
August 19, 2026August 17, 2026 KROS Purchase $10,270 not yetnot yetnot yet
August 18, 2026August 14, 2026 ASND Purchase $492,654 not yetnot yetnot yet
July 17, 2026July 15, 2026 KROS Purchase $10,610 −2.6%not yetnot yet
June 17, 2026June 15, 2026 KROS Purchase $10,190 +2.8%not yetnot yet
June 9, 2026June 5, 2026 IMNM Sale $203,820 +32.8%not yetnot yet
June 9, 2026June 5, 2026 IMNM Purchase $204,260 +32.8%not yetnot yet
June 1, 2026May 29, 2026 ASND Purchase $111,562 +19.6%not yetnot yet
May 27, 2026May 26, 2026 ASND Purchase $95,122 +2.6%not yetnot yet
May 19, 2026May 15, 2026 KROS Purchase $10,580 −3.4%not yetnot yet
May 19, 2026May 15, 2026 IMNM Purchase $103,500 +27.3%not yetnot yet
April 17, 2026April 15, 2026 KROS Purchase $11,700 −15.2%not yetnot yet
March 12, 2026March 10, 2026 IMNM Purchase $43,670 −22.0%not yetnot yet
March 11, 2026March 9, 2026 KROS Purchase $22,420 −19.6%not yetnot yet
June 3, 2025June 3, 2025 IMNM Purchase $46,900 −0.6%+80.8%+84.1%
March 26, 2025March 25, 2025 IMNM Purchase $60,684 +11.7%+152.4%+180.3%
March 25, 2025March 24, 2025 IMNM Purchase $57,470 +16.0%+163.8%+133.4%
August 19, 2024August 16, 2024 IMNM Purchase $97,580 −43.6%−49.2%−45.8%
May 22, 2024May 21, 2024 IMNM Purchase $27,140 +0.5%−53.0%−48.2%
March 7, 2024March 5, 2024 BMRN Sale $172,220 −10.8%−28.5%−31.0%
February 29, 2024February 27, 2024 BMRN Sale $90,350 −17.0%−33.5%−40.2%
August 9, 2023August 7, 2023 BMRN Sale $882,140 −4.3%−23.3%−18.4%
December 15, 2022December 13, 2022 BMRN Sale $106,890 −19.7%−36.9%−28.1%
December 6, 2022December 2, 2022 BMRN Sale $155,967 −11.3%−29.3%−25.3%
November 1, 2022October 31, 2022 BMRN Sale $129,825 +22.8%−23.2%−14.2%
December 2, 2021December 1, 2021 BMRN Sale $130,830 −3.3%+35.3%+30.1%
November 12, 2020November 10, 2020 INCY Sale $66,234 −8.5%−53.4%−54.1%
August 5, 2019August 1, 2019 INCY Sale $146,654 −5.1%+0.4%+3.4%
November 9, 2018November 8, 2018 INCY Purchase $68,765 +31.5%+23.4%+11.5%
September 14, 2017September 13, 2017 IMUX Purchase $40,000 not yetnot yetnot yet
June 15, 2017June 13, 2017 IMUX Purchase $48,000 not yetnot yetnot yet
June 2, 2017May 31, 2017 INCY Purchase $65,900 +9.2%−59.7%−61.6%
May 17, 2017May 15, 2017 INCY Purchase $57,500 −8.7%−64.1%−57.7%
May 2, 2017April 28, 2017 INCY Purchase $62,130 −2.2%−61.6%−63.4%
April 17, 2017April 13, 2017 INCY Purchase $139,660 −1.6%−62.2%−67.2%
April 11, 2017April 7, 2017 INCY Purchase $139,480 −8.5%−64.7%−66.3%
September 11, 2015September 9, 2015 IMUX Purchase $43,100 not yetnot yetnot yet
July 9, 2015July 7, 2015 BMRN Sale $208,605 −26.4%−42.6%−45.2%
March 11, 2015March 9, 2015 BMRN Sale $2,362,553 +3.8%−23.6%−21.6%
March 5, 2015March 5, 2015 BMRN Sale $1,137,000 +7.3%−21.1%−20.8%
November 14, 2014November 12, 2014 BMRN Sale $81,510 +22.1%+26.6%+20.4%
November 12, 2014November 10, 2014 BMRN Sale $348,000 +12.0%+21.0%+23.9%
November 5, 2014November 3, 2014 BMRN Sale $255,990 +10.6%+31.3%+29.6%
October 9, 2014October 8, 2014 IMUX Purchase $75,005 +54.5%−74.1%−75.5%
June 5, 2014June 3, 2014 BMRN Sale $122,400 +5.6%+91.9%+88.9%
August 19, 2013August 15, 2013 BMRN Sale $64,360 −4.1%−11.8%−14.6%
May 15, 2013May 14, 2013 BMRN Sale $1,773,550 −2.2%−26.7%−33.6%
May 15, 2013May 14, 2013 BMRN Sale $1,052,550 −2.2%−26.7%−33.6%
May 2, 2013April 30, 2013 BMRN Sale $194,980 −9.9%−29.0%−31.5%
February 28, 2013February 27, 2013 BMRN Sale $84,690 −2.7%+9.7%+22.8%
December 6, 2012December 4, 2012 BMRN Sale $239,700 +22.1%+18.9%+15.6%
November 19, 2012November 16, 2012 BMRN Sale $384,400 +4.0%+9.3%+5.2%
November 15, 2012November 14, 2012 BMRN Sale $194,000 +3.4%+5.2%−0.3%
November 9, 2012November 7, 2012 BMRN Sale $333,300 +3.2%−2.0%−0.4%
May 15, 2012May 11, 2012 BMRN Sale $1,541,615 −6.1%+33.9%+53.2%
March 13, 2012March 9, 2012 BMRN Sale $516,900 +11.0%+66.8%+63.0%
March 9, 2012March 8, 2012 BMRN Sale $35,000 +8.5%+66.3%+63.1%
March 1, 2012February 29, 2012 BMRN Sale $36,260 +6.7%+58.1%+54.8%
February 28, 2012February 24, 2012 BMRN Sale $178,220 +10.5%+54.8%+47.9%
February 24, 2012February 23, 2012 BMRN Sale $176,550 +9.9%+46.9%+46.4%
August 31, 2011August 30, 2011 BMRN Sale $58,020 +17.4%+10.0%+9.3%
August 22, 2011August 19, 2011 BMRN Sale $53,500 +8.7%+11.5%+9.8%
August 16, 2011August 12, 2011 BMRN Sale $81,300 +7.7%+15.7%+20.5%
August 4, 2011August 2, 2011 BMRN Sale $242,120 +19.2%+24.4%+18.3%
June 8, 2011June 6, 2011 BMRN Sale $54,780 +18.2%+29.3%+32.4%
May 26, 2011May 25, 2011 BMRN Sale $26,940 +11.6%+37.4%+40.6%
May 12, 2011May 10, 2011 BMRN Sale $10,348 +13.2%+42.4%+38.9%
May 5, 2011May 3, 2011 BMRN Sale $204,810 +12.9%+39.7%+31.1%
December 13, 2010December 13, 2010 BMRN Sale $27,430 −14.1%+18.6%+20.1%
December 7, 2010December 6, 2010 BMRN Sale $27,170 −14.9%+17.6%+18.5%
November 23, 2010November 23, 2010 BMRN Sale $27,020 −21.4%+18.9%+18.7%
November 22, 2010November 18, 2010 BMRN Sale $25,990 −19.2%+18.7%+13.9%
November 9, 2010November 8, 2010 BMRN Sale $51,560 −5.3%+19.1%+21.3%
November 4, 2010November 2, 2010 BMRN Sale $191,595 −7.2%+24.8%+23.9%
September 9, 2010September 8, 2010 BMRN Sale $22,220 +7.7%+22.1%+18.0%
August 31, 2010August 30, 2010 BMRN Sale $62,130 +17.5%+26.4%+23.5%
March 1, 2010February 26, 2010 BMRN Purchase $16,064 −5.8%−4.3%+1.1%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Bienaime Jean Jacques traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.